Windtree Therapeutics Stock Scheduled to Reverse Split on Monday, April 22nd (NASDAQ:WINT)

Shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) are scheduled to reverse split on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 22nd.

Windtree Therapeutics Price Performance

Shares of NASDAQ WINT traded down $0.06 during midday trading on Thursday, reaching $0.34. 1,789,008 shares of the company were exchanged, compared to its average volume of 280,849. The stock’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.67. The stock has a market cap of $1.75 million, a P/E ratio of -0.05 and a beta of 0.61. Windtree Therapeutics has a one year low of $0.27 and a one year high of $7.79. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 2.00.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Institutional Trading of Windtree Therapeutics

Several institutional investors have recently modified their holdings of WINT. Citadel Advisors LLC bought a new stake in shares of Windtree Therapeutics in the fourth quarter worth $27,000. Virtu Financial LLC bought a new stake in Windtree Therapeutics during the fourth quarter valued at $28,000. Envestnet Asset Management Inc. boosted its position in Windtree Therapeutics by 894.7% during the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock valued at $32,000 after acquiring an additional 96,515 shares during the last quarter. Millennium Management LLC boosted its position in Windtree Therapeutics by 411.1% during the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock valued at $33,000 after acquiring an additional 64,232 shares during the last quarter. Finally, Vanguard Group Inc. bought a new stake in Windtree Therapeutics during the third quarter valued at $40,000. Institutional investors own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.